Wilson-Robles H, Budke C M, Miller T, Dervisis N, Novosad A, Wright Z, Thamm D H, Vickery K, Burgess K, Childress M, Lori J, Saba C, Rau S, Silver M, Post G, Reeds K, Gillings S, Schleis S, Stein T, Brugmann B, DeRegis C, Smrkovski O, Lawrence J, Laver T
Small Animal Clinical Sciences Department, College of Veterinary Medicine, Texas A&M University, College Station, Texas.
Veterinary Integrative Biosciences Department, College of Veterinary Medicine, Texas A&M University, College Station, Texas.
Vet Comp Oncol. 2017 Dec;15(4):1564-1571. doi: 10.1111/vco.12302. Epub 2017 Apr 17.
In humans geographical differences in the incidence and presentation of various cancers have been reported. However, much of this information has not been collected in veterinary oncology.
The purpose of this study was to determine if a geographic difference in progression free survival exists for dogs with lymphoma treated within the US.
Medical records of 775 cases of canine lymphoma from 3 US regions (west, south and north), treated with CHOP chemotherapy, were retrospectively evaluated. Cases were collected from referral institutions and were required to have received at least one doxorubicin treatment and have follow up information regarding time to progression.
Significant differences in sex (p = 0.05), weight (p = 0.049), stage (p < 0.001), immunophenotype (p = <0.001), and number of doxorubicin doses (p = 0.001) were seen between regions. Upon univariate analysis, progression free survival (PFS) differed by region (p = 0.006), stage (p = 0.009), sub-stage (p = 0.0005), and immunophenotype (p = 0.001). A multivariable Cox regression model showed that dogs in the western region had a significantly shorter PFS when compared to the south and east.
PFS was significantly affected by stage, sub-stage and phenotype.
据报道，人类各种癌症的发病率和临床表现存在地域差异。然而，兽医肿瘤学中尚未收集到许多此类信息。
本研究的目的是确定在美国接受治疗的淋巴瘤犬的无进展生存期是否存在地域差异。
回顾性评估了来自美国3个地区（西部、南部和北部）的775例接受CHOP化疗的犬淋巴瘤病例的医疗记录。病例来自转诊机构，要求至少接受过一次阿霉素治疗，并具有关于疾病进展时间的随访信息。
各地区之间在性别（p = 0.05）、体重（p = 0.049）、分期（p < 0.001）、免疫表型（p = <0.001）和阿霉素剂量数（p = 0.001）方面存在显著差异。单因素分析显示，无进展生存期（PFS）因地区（p = 0.006）、分期（p = 0.009）、亚分期（p = 0.0005）和免疫表型（p = 0.001）而异。多变量Cox回归模型显示，与南部和东部相比，西部地区的犬无进展生存期明显较短。
无进展生存期受分期、亚分期和表型的显著影响。
